uniQure’s (QURE) “Buy” Rating Reiterated at HC Wainwright

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $25.00 price target on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 408.13% from the stock’s current price.

Several other analysts also recently weighed in on the company. StockNews.com upgraded uniQure to a “sell” rating in a research report on Friday, March 1st. The Goldman Sachs Group lowered shares of uniQure from a “buy” rating to a “neutral” rating and cut their price target for the stock from $63.00 to $8.00 in a report on Thursday, February 29th. Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 target price on shares of uniQure in a report on Tuesday, January 16th. Finally, Mizuho reduced their price target on uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $31.91.

uniQure Stock Performance

Shares of NASDAQ:QURE traded up $0.10 during midday trading on Wednesday, reaching $4.92. 509,794 shares of the company traded hands, compared to its average volume of 923,309. The firm’s fifty day moving average price is $5.03 and its two-hundred day moving average price is $5.89. The firm has a market capitalization of $235.37 million, a price-to-earnings ratio of -0.75 and a beta of 0.98. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49. uniQure has a 12 month low of $4.25 and a 12 month high of $22.48.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.01. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. The company had revenue of $6.69 million during the quarter, compared to analyst estimates of $3.20 million. On average, equities analysts expect that uniQure will post -4.49 earnings per share for the current year.

Insider Activity

In other news, COO Pierre Caloz sold 9,455 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at $554,110.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at $554,110.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 27,904 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the sale, the chief executive officer now directly owns 440,839 shares of the company’s stock, valued at approximately $2,799,327.65. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,265 shares of company stock valued at $339,845. 4.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC purchased a new position in shares of uniQure during the third quarter worth $31,000. China Universal Asset Management Co. Ltd. raised its stake in shares of uniQure by 222.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 4,315 shares during the last quarter. Nomura Holdings Inc. acquired a new position in shares of uniQure in the 3rd quarter valued at about $67,000. Laurion Capital Management LP acquired a new stake in uniQure during the third quarter worth about $73,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in uniQure during the fourth quarter worth about $86,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.